Cardiac Arrest

Researchers are working to create risk prediction models that help identify patients with a high risk of developing serious cardiovascular problems. The study focuses on individuals with structural, rhythm-related, or inflammatory cardiovascular diseases and aims to improve early detection of those at risk. This observational study is sponsored by the Medical University Innsbruck and includes adults 18 years and older. Participants in this study have their clinical data and risk factors recorded to better understand their cardiovascular condition. There are no specific treatments or interventions given as part of the study since it is observational. The study will follow patients for up to four years to observe outcomes related to cardiovascular events and hospitalizations. During the study, researchers will monitor events such as cardiovascular mortality, stroke, heart attacks, hospital stays due to heart failure, and other severe heart-related conditions. Participants will be assessed regularly through clinical data collection without additional procedures or treatments. The study aims to gather detailed information over time to improve risk assessment and patient care for cardiovascular diseases.

Noncommunicable diseases like type 2 diabetes and cardiovascular disease cause more deaths worldwide than any other conditions, with a growing impact especially in low- and middle-income countries. Cardiovascular disease CVD is a leading cause of death globally, and its prevalence is rising despite awareness efforts. Diet and nutrition are important factors influencing these diseases, and this research explores the role of a traditional Chinese medicine nutritional drink in supporting cardiovascular health. The study evaluates the effects of the Perfect Heartio drink, a nutritional supplement made from diluted herbal extracts traditionally used in Chinese medicine. Participants will consume 15 grams of the drink twice daily for 12 weeks while their compliance is monitored. This intervention is being studied to assess its potential in improving heart and blood vessel function by measuring various cardiovascular health indicators. Participants will be assessed at the start and at weeks 4, 8, and 12 for lipid profiles, heart inflammation, heart injury, and heart remodeling. Quality of life and self-perceived health status will also be evaluated over these timepoints. The study includes healthy adults aged 18 and above who agree to follow the intervention plan and attend follow-up visits. Monitoring throughout the study will help researchers understand the drinks impact on cardiovascular health markers over the 12-week period.

The 100-Year Human Aging Study is a long-term observational research project enrolling adult participants to undergo detailed multi-system health screenings and follow them throughout their lives until death. The study aims to identify which health measurements taken at enrollment and repeatedly over time can predict overall mortality, cause-specific death, serious diseases, and functional disability. It addresses the current lack of validated longevity measures by generating data on how various physiological and cognitive functions relate to aging outcomes. Participants undergo a comprehensive clinical screening that includes tests of cardiorespiratory fitness, strength, mobility, neurocognitive performance, sensory functions, and metabolic health. Structural imaging assessments like DEXA scans, echocardiography, electrocardiography, spirometry, retinal photography, and vascular ultrasound are performed. Laboratory tests and detailed medical, social, and environmental histories are also collected. The study allows participation from single tests up to a full two-visit screening, with repeat testing encouraged to track health changes over time. Throughout the study, participants receive individualized reports with investigational estimates of biological age and predicted mortality risks, which are being evaluated against actual health outcomes. Researchers collect data continuously on mortality, disease occurrence, disability, and health behavior changes. The study involves ongoing follow-up with periodic assessments and aims to preserve all collected data for future analyses, with participant involvement potentially spanning their entire lifespan.

The GENESIS clinical study aims to map HLA genetic variation in the Greek population and evaluate possible correlations with selected underlying diseases. It is a multicenter, prospective, non-interventional clinical study targeting 12,000 subjects over an anticipated duration of 36 months, with the goal of creating a pilot HLA map for medical research and possible clinical applications. Each subject will complete one visit at a participating site and provide demographic information, including date of birth, gender, race, ancestry, height, and weight, as well as information about smoking or vaping, alcohol consumption, arterial blood pressure, diagnosed diseases, and current treatments. Recent clinical laboratory results from up to 12 months before sample collection may also be collected when available, including blood count, metabolic, liver enzyme, and biochemical parameters. Two buccal swabs will be collected from each subject for DNA extraction and HLA genotyping analysis. Selected DNA samples will also undergo low-pass whole genome sequencing to further investigate associations between the HLA region and autoimmune diseases. After the analysis is completed, an individualized ancestry report will be securely available to study subjects if they elect to access it.

Hypertension is a common chronic condition and a key risk factor for heart and brain blood vessel diseases, posing a significant public health challenge. This research aims to explore the relationship between various biomarkers and negative health outcomes in adults with hypertension. The study focuses on adults 18 years and older diagnosed with hypertension, regardless of race or ethnicity. Participants will be observed without any treatment intervention as this is an observational study. At the start of the study, participants undergo physical exams, complete questionnaires, and provide blood samples. Researchers will then monitor these participants over time to track mortality rates, including deaths from any cause and specifically cardiovascular-related deaths. Throughout the study, participants health and outcomes will be followed for up to one year after enrollment. The study collects data through physical exams, surveys, and blood specimen analysis to assess mortality outcomes. This approach helps researchers understand how biomarkers may relate to survival and cardiovascular risks in people with hypertension.

Researchers are evaluating the potential benefits of implanting an implantable cardioverter defibrillator ICD in patients with coronary artery disease who have survived cardiac arrest caused by ventricular fibrillation or sustained ventricular tachycardia. These patients have undergone complete revascularization and have a left ventricular ejection fraction LVEF above 35%. The study aims to assess whether ICD implantation can improve survival outcomes compared to standard medical therapy. Participants are randomly assigned to one of two groups one group receives an ICD implanted either during admission or within 4 weeks after discharge from the initial cardiac event, while the other group receives guideline-directed medical therapy without ICD implantation. The study compares these approaches to understand the effect of ICDs on survival in this patient population. During the study, participants will be monitored for outcomes including all-cause mortality over a five-year period, as well as mortality related to cardiovascular causes at one year. Researchers will collect data on sudden cardiovascular death and cardiovascular death within the first year. The trial includes follow-up assessments to track these outcomes and the overall health of participants throughout the study duration.

Cardiovascular disease CVD is a leading cause of death worldwide and unhealthy lifestyle behaviors are well-known risk factors. This study evaluates whether a digital lifestyle intervention developed within Swedish primary healthcare can improve important cardiovascular health outcomes and promote healthier lifestyle behaviors in patients aged 40 to 60 years. Participants are recruited from multiple centers in Sweden and randomized to either the intervention or control group with standard care. Participants in the intervention group receive support through a digital lifestyle program that includes lectures, home assignments, and group meetings, along with personalized digital feedback from healthcare providers. Both groups receive standard care, which is one structured health dialogue focused on lifestyle habits. The study measures outcomes at 6 months post-randomization, including LDL-cholesterol as the primary outcome, and several secondary outcomes related to cholesterol levels, blood glucose, blood pressure, weight, lifestyle behaviors, and quality of life. Throughout the study, participants undergo assessments of blood lipids, glucose, blood pressure, body measurements, and lifestyle factors such as diet, physical activity, sleep, stress, alcohol, and tobacco use. Researchers also evaluate cardiovascular risk scores and collect participant feedback on using the digital intervention. The total study duration is 6 months post-randomization with data collected to assess the impact of the digital program compared to standard care.

Researchers are evaluating a family-centred approach to prevent cardiovascular diseases CVD among adolescents and their families in Uganda. This 5-year study focuses on reducing risk factors like unhealthy diet and physical inactivity that contribute to CVD and other non-communicable diseases NCDs. The study adapts a proven intervention from Asia to the Ugandan context, aiming to support healthier lifestyle behaviors during the critical adolescence period when habits form that affect adult health. The study includes two groups one receiving the FaCe-D intervention, which involves home visits by Village Health Teams delivering diet, physical activity, and health messaging and a control group receiving standard care with usual health promotion activities. The study is divided into three phases adapting the intervention, implementing it, and evaluating its effectiveness and feasibility in 32 villages. Participants will be involved for at least 12 months, during which researchers will assess changes in cardiovascular health and sleep quality. Evaluations include monitoring behavior changes, health outcomes, and implementation costs. The study also considers adoption and feasibility to understand how well the intervention works in real community settings.

This research aims to understand how menopause affects the risk of cardiovascular diseases such as atherosclerosis, heart attacks, and strokes in women. It focuses on the time around menopause when estrogen production stops, which is linked to a higher risk of these conditions. The study will follow 200 women from before menopause to at least 10 years after, using advanced methods to observe changes in blood vessels, the heart, and the brain, along with microRNA analysis of blood and tissue samples. Participants will be observed over a long period with repeated assessments before menopause and at 1, 3, 5, 10, and 20 years after menopause. These assessments include invasive and non-invasive measures of vascular function, as well as monitoring changes in skeletal muscle proteins and RNA expression from muscle and blood samples. Blood pressure will also be tracked regularly during this time. Women involved in the study will undergo detailed cardiovascular and biological evaluations at various time points throughout the study. This includes tests of blood vessel function, muscle tissue analysis, and blood sample collections. The researchers will also monitor blood pressure and other health indicators to understand the long-term impact of menopause on cardiovascular health. The total participation may last over 20 years, providing extensive data on how menopause influences disease risk over time.

Researchers are evaluating the safety and performance of the Polymer Free Sirolimus Eluting Coronary Stent Vivo ISAR in patients with coronary artery disease CAD. This observational registry focuses on individuals treated with this specific stent and planned for a short dual antiplatelet therapy DAPT of up to 3 months. The study aims to collect real-world data on clinical outcomes including safety and effectiveness over a 12-month period. Participants in this single-arm registry have undergone percutaneous coronary intervention PCI using the Vivo ISAR stent and will receive standard care short DAPT treatment for no more than 3 months. The study does not affect treatment choices or standard care procedures. After the PCI, eligible patients will be invited to join the registry and followed up at 1 month, 3 months, and 12 months. During the study, researchers will collect baseline medical data and conduct telephonic follow-ups at 30 days, 3 months, and 12 months. These follow-ups will check on medication use, laboratory assessments, adverse events, and any further interventions. The main outcomes measured include ischemic and bleeding events at 12 months, along with secondary outcomes such as mortality, heart attacks, strokes, stent thrombosis, and need for additional vessel treatments. The total participation duration is one year from the PCI procedure.